These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32976855)

  • 1. Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone.
    Ganjali S; Bianconi V; Penson PE; Pirro M; Banach M; Watts GF; Sahebkar A
    Metabolism; 2020 Dec; 113():154375. PubMed ID: 32976855
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 and cardiovascular disease.
    Guijarro C
    Clin Investig Arterioscler; 2020; 32(6):263-266. PubMed ID: 33213825
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
    Barkas F; Milionis H; Anastasiou G; Liberopoulos E
    Med Hypotheses; 2021 Jan; 146():110452. PubMed ID: 33333472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid management for the prevention of cardiovascular disease.
    Schaefer JR
    Curr Pharm Des; 2011; 17(9):852-60. PubMed ID: 21418030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins in COVID-19: is there any foundation?
    Lima Martínez MM; Contreras MA; Marín W; D'Marco L
    Clin Investig Arterioscler; 2020; 32(6):278-281. PubMed ID: 32718669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and cardiovascular risks.
    Lee JW
    Int Anesthesiol Clin; 2005; 43(2):55-68. PubMed ID: 15795562
    [No Abstract]   [Full Text] [Related]  

  • 7. Plausible Positive Effects of Statins in COVID-19 Patient.
    Vitiello A; Ferrara F
    Cardiovasc Toxicol; 2021 Oct; 21(10):781-789. PubMed ID: 34255300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications.
    Nägele MP; Haubner B; Tanner FC; Ruschitzka F; Flammer AJ
    Atherosclerosis; 2020 Dec; 314():58-62. PubMed ID: 33161318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: Direct and Indirect Mechanisms of Statins.
    Pawlos A; Niedzielski M; Gorzelak-Pabiś P; Broncel M; Woźniak E
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target.
    Cesaro A; Riccio C; Calabrò P
    Monaldi Arch Chest Dis; 2021 May; 91(2):. PubMed ID: 33942600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins in COVID-19 infection: A rehash of old themes or truly a new hope?
    Jia X; Virani SS
    J Clin Lipidol; 2021; 15(3):399-401. PubMed ID: 33994121
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of statins on myocarditis: A review of underlying molecular mechanisms.
    Parsamanesh N; Karami-Zarandi M; Banach M; Penson PE; Sahebkar A
    Prog Cardiovasc Dis; 2021; 67():53-64. PubMed ID: 33621589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).
    Li SD; Zhang SY; Peng B
    Chin Med J (Engl); 2020 Nov; 134(4):407-409. PubMed ID: 33617183
    [No Abstract]   [Full Text] [Related]  

  • 14. The activation of mTOR is required for monocyte pro-inflammatory response in patients with coronary artery disease.
    Gao S; Liu W; Zhuo X; Wang L; Wang G; Sun T; Zhao Z; Liu J; Tian Y; Zhou J; Yuan Z; Wu Y
    Clin Sci (Lond); 2015 Apr; 128(8):517-26. PubMed ID: 25428582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines and guidance in lipid modification.
    Hennekens CH; Pfeffer MA
    Trends Cardiovasc Med; 2015 May; 25(4):348-50. PubMed ID: 25497277
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging therapies for residual risk.
    Mehra S; Movahed H; Movahed A
    Rev Cardiovasc Med; 2012; 13(1):e24-31. PubMed ID: 22565535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential for clomiphene, a selective estrogen receptor modulator, in the treatment of COVID-19.
    Ghasemnejad-Berenji M; Pashapour S; Ghasemnejad-Berenji H
    Med Hypotheses; 2020 Dec; 145():110354. PubMed ID: 33129007
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.
    Shah PK
    Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic determinants of response to statins.
    Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.